Tipsheet
What matters at India’s listed companies
Pharmaceuticals · Micro cap

Deccan Healthcare taps internal candidate as CFO after sudden exit

Tushar Mandal, an eight-year veteran, takes over from Parth Palera who resigned last week. A governance fill-up, not a surprise.


Mkt cap₹33.11 cr
P/E13.31×
ROE1.09%
Debt / eq.0.01
8 years Tenure of new CFO with the company

What's new

  • Tushar Mandal appointed CFO effective 2 July 2026.
  • He replaces Parth Palera, who resigned on 25 June to pursue another opportunity.
  • Mandal has been with Deccan Healthcare for over 8 years handling finance.

Why this matters

For a nano-cap pharma firm with a ₹33 crore market cap, an internal CFO appointment signals stability after an unexpected departure. But with no terms disclosed and the prior CFO leaving abruptly, the board still needs to demonstrate longer-term governance depth.

What we're watching

  • Any further C-suite changes at the company.
  • Whether the company discloses Mandal's compensation package.
  • If the resignation is linked to any broader governance issues.

The full read

Deccan Healthcare filled the CFO vacancy quickly. Parth Palera resigned on 25 June; the board appointed Tushar Mandal, an 8‑year company veteran, effective 2 July 2026. No surprise there — an internal hire for a known opening. For a ₹33 crore pharma firm, the move provides governance stability after an unexpected exit, but the lack of disclosed terms means the market learns nothing new. The open question is whether more C‑suite changes follow.

Questions answered

Why did the previous CFO resign?
Parth Palera resigned on 25 June to pursue a different professional opportunity. The company did not elaborate.
Is the new CFO an outsider or insider?
Tushar Mandal is an insider — he has been with Deccan Healthcare for over 8 years managing its financial operations.
Why is this appointment considered routine?
Filling a known vacancy with an internal candidate reduces uncertainty. For a nano-cap stock, the market likely anticipated a replacement, so the filing lacks surprise.
What are the terms of Mr Mandal's employment?
The company did not disclose any terms of his employment in the filing.
Mentioned: Tushar Mandal · Parth Palera · 2 July 2026
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Deccan Health Care Ltd.

Pharmaceuticals
₹33 cr
P/E 13.28×

Latest quarter · Mar 2026

Sales₹21 cr
Net profit₹0 cr
Op. margin+4.3%
EPS₹0.14

Strength & growth

Debt / equity0.01×
Current ratio6.77×
Financials via Tijori — a research aid, not investment advice.DECCAN on Tijori